News from the FDA/CDC

Cigarette smoking at lowest level ever


 

FROM MMWR

The prevalence of cigarette smoking among adults was down to 14% in 2017, the lowest level recorded since monitoring began in 1965, according to the Centers for Disease Control and Prevention.

Prevalence of current tobacco product use in adults, 2017

“This new all-time low in cigarette smoking among U.S. adults is a tremendous public health accomplishment, and it demonstrates the importance of continued proven strategies to reduce smoking,” CDC Director Robert Redfield said in a written statement.

In 2017, 19.3% of adults aged 18 years and older – approximately 47.4 million Americans – reported current use of some type of tobacco product, and current use of combustible tobacco was 16.7%, Teresa W. Wang, PhD, of the CDC’s National Center for Chronic Disease Prevention and Health Promotion, Atlanta, and her associates reported in the Morbidity and Mortality Weekly Report. Current use was defined as use every day or some days, with an added requirement of at least 100 cigarettes in a lifetime added for cigarette smokers.

Data from the National Health Interview Survey showed that from 2016 to 2017, current use declined for any tobacco product, any combustible tobacco product, cigarettes, smokeless tobacco, and the combination of two or more tobacco products. The most common combination in 2017 was cigarettes and e-cigarettes, which was reported by 30.1% of the 9 million adults who used more than one product, Dr. Wang and her associates said.

Prevalence of current tobacco use was higher among men than women (24.8% vs. 14.2%), and adults aged 25-44 years (22.5%) had the highest level by age, followed by those aged 45-64 years (21.3%), 18-24 years (18.3%), and 65 years or older (11%). Use by race/ethnicity was highest among American Indian/Alaska Natives (29.8%), with the Midwest putting up the highest prevalence by region at 23.5%, they said.

“Although cigarette smoking among U.S. adults has declined considerably, tobacco products have evolved in recent years to include various combustible, noncombustible, and electronic products,” Dr. Wang and her associates wrote. “Implementation of evidence-based tobacco control interventions that address the diversity of tobacco products used by U.S. adults, in coordination with regulation of tobacco product manufacturing, marketing, and sales, can reduce tobacco-related disease and death in the United States.”

SOURCE: Wang TW et al. MMWR. 2018 Nov 9;67[44]:1225-32.

Recommended Reading

NIH launches HEAL Initiative to combat opioid crisis
MDedge Hematology and Oncology
Do free meals to physicians affect opioid prescribing?
MDedge Hematology and Oncology
Fentanyl analogs nearly double their overdose death toll
MDedge Hematology and Oncology
For smokers, the ends may not justify the ENDS
MDedge Hematology and Oncology
E-cigarettes: Prices down, sales up
MDedge Hematology and Oncology
Confirmed: Growth in overdose deaths is exponential
MDedge Hematology and Oncology
Coagulopathy outbreak underscores danger of synthetic cannabinoids
MDedge Hematology and Oncology
House, Senate agree on broad opioid legislation
MDedge Hematology and Oncology
Does America have a gabapentinoid problem?
MDedge Hematology and Oncology
Drug overdose deaths down since late 2017
MDedge Hematology and Oncology